Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease

Clinical trial NCT06989359 · RECRUITING

Trial details

NCT number: NCT06989359
Sponsor: ADARx Pharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

IgAN C3G Complement-mediated Kidney Disease IgA Nephropathy (IgAN)IC-MPGN

Start date: 2025-08-28
Primary completion: 2028-12-31
Enrollment: 45

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.